Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety
Posted inDiabetes & Endocrinology Nephrology news

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type 2 diabetes trials and a manageable hyperkalemia signal.
Less Sitting, More Sleep and MVPA Linked to Better Glycaemic Stability in Children with Type 1 Diabetes: A 2‑Year Compositional Analysis
Posted inDiabetes & Endocrinology news Pediatrics

Less Sitting, More Sleep and MVPA Linked to Better Glycaemic Stability in Children with Type 1 Diabetes: A 2‑Year Compositional Analysis

A longitudinal compositional analysis of 83 children with type 1 diabetes found that reallocating daily time away from sedentary behaviour toward sleep or moderate‑to‑vigorous physical activity (MVPA) was associated with lower HbA1c and interstitial glucose over two years.